logo-loader

Tiziana Life Sciences to trial 'first ever take-home capsules' of Foralumab for Crohn’s Disease

Published: 07:38 11 Nov 2020 GMT

Tiziana Life Sciences PLC's (LON:TILS) (NASDAQ:TLSA) CEO Kunwar Shailubhai speaks to Proactive's Andrew Scott following the news they're collaborating with Parexel Biotech to conduct a global Phase 1b/2 trial with enteric-coated capsules of formulated Foralumab as a therapy for patients with moderate to severe Crohn’s Disease. The study will evaluate the safety, tolerability, and clinical activity of escalating doses of orally administered capsules of Foralumab.

Proactive Analyst expects "some good news over the next 1-2 months" from...

Proactive Research Analyst Robin Davison talks to Thomas Warner about his new research note on Tiziana Life Sciences Ltd (NASDAQ:TLSA), which focuses on what he expects from the clinical-stage biopharmaceutical company over the next few months. He says Tiziana is approaching a significant...

on 28/7/23